Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

NCT05510427 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Per PI's request

Conditions

Cholangiocarcinoma
Liver Cancer

Interventions

DRUG: Infigratinib
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]